Immuneering (IMRX) Cash & Equivalents: 2020-2024
Historic Cash & Equivalents for Immuneering (IMRX) over the last 4 years, with Sep 2024 value amounting to $45.2 million.
- Immuneering's Cash & Equivalents fell 33.56% to $45.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $45.2 million, marking a year-over-year decrease of 33.56%. This contributed to the annual value of $59.4 million for FY2023, which is 18.22% down from last year.
- According to the latest figures from Q3 2024, Immuneering's Cash & Equivalents is $45.2 million, which was down 24.31% from $59.7 million recorded in Q2 2024.
- Over the past 5 years, Immuneering's Cash & Equivalents peaked at $106.9 million during Q3 2021, and registered a low of $37.1 million during Q4 2020.
- Moreover, its 3-year median value for Cash & Equivalents was $72.6 million (2022), whereas its average is $72.0 million.
- In the last 5 years, Immuneering's Cash & Equivalents soared by 101.91% in 2021 and then crashed by 42.58% in 2024.
- Quarterly analysis of 5 years shows Immuneering's Cash & Equivalents stood at $37.1 million in 2020, then skyrocketed by 101.91% to $74.9 million in 2021, then fell by 3.01% to $72.6 million in 2022, then decreased by 18.22% to $59.4 million in 2023, then crashed by 33.56% to $45.2 million in 2024.
- Its Cash & Equivalents was $45.2 million in Q3 2024, compared to $59.7 million in Q2 2024 and $66.3 million in Q1 2024.